Zobrazeno 1 - 10
of 516
pro vyhledávání: '"James N Ingle"'
Autor:
Junmei Cairns, James N Ingle, Lawrence D Wickerham, Richard Weinshilboum, Mohan Liu, Liewei Wang
Publikováno v:
PLoS Genetics, Vol 13, Iss 10, p e1007031 (2017)
Tamoxifen is one of the most commonly employed endocrine therapies for patients with estrogen receptor α (ERα)-positive breast cancer. Unfortunately the clinical benefit is limited due to intrinsic and acquired drug resistance. We previously report
Externí odkaz:
https://doaj.org/article/c07169557d3f4904b68253651854ee88
Autor:
Kevin J Thompson, James N Ingle, Xiaojia Tang, Nicholas Chia, Patricio R Jeraldo, Marina R Walther-Antonio, Karunya K Kandimalla, Stephen Johnson, Janet Z Yao, Sean C Harrington, Vera J Suman, Liewei Wang, Richard L Weinshilboum, Judy C Boughey, Jean-Pierre Kocher, Heidi Nelson, Matthew P Goetz, Krishna R Kalari
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0188873 (2017)
The inflammatory tumoral-immune response alters the physiology of the tumor microenvironment, which may attenuate genomic instability. In addition to inducing inflammatory immune responses, several pathogenic bacteria produce genotoxins. However the
Externí odkaz:
https://doaj.org/article/53af000f849c4c2dad2a356dba3d40b8
Autor:
Huanyao Gao, Lixuan Wei, Shreya Indulkar, Thanh Thanh. L. Nguyen, Duan Liu, Ming-Fen Ho, Cheng Zhang, Hu Li, Richard M. Weinshilboum, James N. Ingle, Liewei Wang
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-14 (2024)
Abstract Background Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor (AR) is also expressed in the vast majority (80–90%) of ERα-positi
Externí odkaz:
https://doaj.org/article/0906792d3b1b42248df6ef4f3c484ff2
Autor:
Roberto A. Leon-Ferre, Kaitlyn R. Whitaker, Vera J. Suman, Tanya Hoskin, Karthik V. Giridhar, Raymond M. Moore, Ahmad Al-Jarrad, Sarah A. McLaughlin, Donald W. Northfelt, Katie N. Hunt, Amy Lynn Conners, Ann Moyer, Jodi M. Carter, Krishna Kalari, Richard Weinshilboum, Liewei Wang, James N. Ingle, Keith L. Knutson, Stephen M. Ansell, Judy C. Boughey, Matthew P. Goetz, Jose C. Villasboas
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024)
Abstract Background Tumor immune infiltration and peripheral blood immune signatures have prognostic and predictive value in breast cancer. Whether distinct peripheral blood immune phenotypes are associated with response to neoadjuvant chemotherapy (
Externí odkaz:
https://doaj.org/article/b975d37e612b41688982be8b1d8df388
Autor:
Roberto A. Leon-Ferre, Jodi M. Carter, David Zahrieh, Jason P. Sinnwell, Roberto Salgado, Vera J. Suman, David W. Hillman, Judy C. Boughey, Krishna R. Kalari, Fergus J. Couch, James N. Ingle, Maschenka Balkenhol, Francesco Ciompi, Jeroen van der Laak, Matthew P. Goetz
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Operable triple-negative breast cancer (TNBC) has a higher risk of recurrence and death compared to other subtypes. Tumor size and nodal status are the primary clinical factors used to guide systemic treatment, while biomarkers of proliferat
Externí odkaz:
https://doaj.org/article/76fed00f45b74d1e9623e4f305759050
Autor:
Anne Gingery, Malayannan Subramaniam, Kevin S Pitel, Jordan M Reese, Muzaffer Cicek, Laurence B Lindenmaier, James N Ingle, Matthew P Goetz, Russell T Turner, Urszula T Iwaniec, Thomas C Spelsberg, John R Hawse
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e98219 (2014)
Endoxifen has recently been identified as the predominant active metabolite of tamoxifen and is currently being developed as a novel hormonal therapy for the treatment of endocrine sensitive breast cancer. Based on past studies in breast cancer cells
Externí odkaz:
https://doaj.org/article/67822f0f26c34e9d85cce6b81062378a
Autor:
Mateusz Opyrchal, Jeffrey L Salisbury, Shuya Zhang, James McCubrey, John Hawse, Mattew P Goetz, Gwen A Lomberk, Tufia Haddad, Amy Degnim, Carol Lange, James N Ingle, Evanthia Galanis, Antonino B D'Assoro
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e96995 (2014)
Development of endocrine resistance during tumor progression represents a major challenge in the management of estrogen receptor alpha (ERα) positive breast tumors and is an area under intense investigation. Although the underlying mechanisms are st
Externí odkaz:
https://doaj.org/article/c7da98dd6ce74f7c926be89deef9be93
Autor:
Eike-Benjamin Braune, Felix Geist, Xiaojia Tang, Krishna Kalari, Judy Boughey, Liewei Wang, Roberto A. Leon-Ferre, Antonino B. D’Assoro, James N. Ingle, Matthew P. Goetz, Julian Kreis, Kang Wang, Theodoros Foukakis, Anita Seshire, Dirk Wienke, Urban Lendahl
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-22 (2024)
Abstract Background Dysregulated Notch signalling contributes to breast cancer development and progression, but validated tools to measure the level of Notch signalling in breast cancer subtypes and in response to systemic therapy are largely lacking
Externí odkaz:
https://doaj.org/article/f8003a5a92c14e34b1fab373cd274d48
Autor:
John R Hawse, Malayannan Subramaniam, Muzaffer Cicek, Xianglin Wu, Anne Gingery, Sarah B Grygo, Zhifu Sun, Kevin S Pitel, Wilma L Lingle, Matthew P Goetz, James N Ingle, Thomas C Spelsberg
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e54613 (2013)
Endoxifen, a cytochrome P450 mediated tamoxifen metabolite, is being developed as a drug for the treatment of estrogen receptor (ER) positive breast cancer. Endoxifen is known to be a potent anti-estrogen and its mechanisms of action are still being
Externí odkaz:
https://doaj.org/article/53b65588edee4aa2a677eafd0d4587e4
Autor:
Swaathi Jayaraman, Xinyan Wu, Krishna R. Kalari, Xiaojia Tang, Mary J. Kuffel, Elizabeth S. Bruinsma, Shahrzad Jalali, Kevin L. Peterson, Cristina Correia, Rachel A. Kudgus, Scott H. Kaufmann, Santosh Renuse, James N. Ingle, Joel M. Reid, Matthew M. Ames, Alan P. Fields, Matthew J. Schellenberg, John R. Hawse, Akhilesh Pandey, Matthew P. Goetz
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-16 (2023)
Abstract Endoxifen, a secondary tamoxifen metabolite, is a potent antiestrogen exhibiting estrogen receptor alpha (ERα) binding at nanomolar concentrations. Phase I/II clinical trials identified clinical activity of Z-endoxifen (ENDX), in endocrine-
Externí odkaz:
https://doaj.org/article/809fda6ff0ea4cad83dc611d55814884